Pantoprazole with Domperidone Capsules
The combination of domperidone and pantoprazole is marketed by Rewine Pharmaceuticals.
Pantoprazole acts by selectively inhibiting the H+/K+-ATPase enzyme in the secretory canaliculus of the stimulated parietal cell. Domperidone stimulates GI activity by acting as a competitive antagonist at dopamine D2-receptors.
Pantoprazole: Diarrhoea, dizziness, pruritus, skin rashes, GIT infections; anaphylaxis, angioedema, chest pain, dyspnoea, erythema multiforme, gastroenteritis, hyperglycaemia, infection, Inj site reaction, jaundice, optic neuropathy, anterior ischaemia, pancreatitis, speech disorder. Domperidone: Headache, insomnia, nervousness, dizziness, thirst, lethargy, irritability, GI disturbances, hot flushes, mastalgia, galactorrhoea, gynaecomastia, menstrual irregularities, rash, pruritus, urticaria, stomatitis, conjunctivitis, urinary frequency, dysuria, oedema, palpitations, leg cramps, asthaenia, drug intolerance.
Lactation. Pantoprazole: Not recommended in child <12 years. Long-term therapy may lead to bacterial overgrowth in the GIT. Domperidone: Increases serum prolactin levels resulting to galactorrhoea in females and gynaecomastia in males. Hypertensive crisis in patients with phaeochromocytoma.
Care should be exercised when domperidone is administered in combination with MAO inhibitors.
Gastro-oesophageal reflux disease, Dyspepsia
Adult: Per tablet/capsule contains pantoprazole 40 mg and domperidone 10 mg: 1 tablet/capsule once daily.
Developed and Managed by Infocom Network Private Limited.